Literature DB >> 7815504

Neutralization of respiratory syncytial virus after cell attachment.

C Osiowy1, R Anderson.   

Abstract

Little is known about the mechanisms of antibody-mediated neutralization of respiratory syncytial virus (RSV) which causes recurrent infections in human despite the virtually universal presence of neutralizing serum antibodies. Human serum neutralization titers showed strong correlation with post-cell-attachment neutralizing titers for both RSV-convalescent sera and control sera but showed less strong correlation with cell-attachment blocking titers. Neutralization was effective for the first 60 min of infection, indicating that immune serum-mediated neutralization of RSV infection largely involves inhibition of early events following cell attachment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815504      PMCID: PMC188702     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  IgG-neutralized influenza virus undergoes primary, but not secondary uncoating in vivo.

Authors:  R J Rigg; A S Carver; N J Dimmock
Journal:  J Gen Virol       Date:  1989-08       Impact factor: 3.891

Review 2.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

3.  Immunity to and frequency of reinfection with respiratory syncytial virus.

Authors:  C B Hall; E E Walsh; C E Long; K C Schnabel
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

4.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  Respiratory syncytial virus proteins: identification by immunoprecipitation.

Authors:  J M Bernstein; J F Hruska
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

6.  Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus.

Authors:  C L Lamprecht; H E Krause; M A Mufson
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

7.  Respiratory syncytial virus in early infancy. Circulating antibody and the severity of infection.

Authors:  F W Bruhn; A S Yeager
Journal:  Am J Dis Child       Date:  1977-02

8.  Antibodies to respiratory syncytial virus polypeptides and their significance in human infection.

Authors:  K A Ward; P R Lambden; M M Ogilvie; P J Watt
Journal:  J Gen Virol       Date:  1983-09       Impact factor: 3.891

9.  Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level.

Authors:  W P Glezen; A Paredes; J E Allison; L H Taber; A L Frank
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

10.  Direct observation of the budding and fusion of an enveloped virus by video microscopy of viable cells.

Authors:  T Bächi
Journal:  J Cell Biol       Date:  1988-11       Impact factor: 10.539

View more
  7 in total

Review 1.  Genetic and structural determinants of virus neutralizing antibodies.

Authors:  J E Crowe; R O Suara; S Brock; N Kallewaard; F House; J H Weitkamp
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

Authors:  M J Edwards; N J Dimmock
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Different mechanisms of antibody-mediated neutralization of parvoviruses revealed using the Fab fragments of monoclonal antibodies.

Authors:  Christian D S Nelson; Laura M Palermo; Susan L Hafenstein; Colin R Parrish
Journal:  Virology       Date:  2007-01-09       Impact factor: 3.616

4.  Identification of nucleolin as a cellular receptor for human respiratory syncytial virus.

Authors:  Farnoosh Tayyari; David Marchant; Theo J Moraes; Wenming Duan; Peter Mastrangelo; Richard G Hegele
Journal:  Nat Med       Date:  2011-08-14       Impact factor: 53.440

5.  Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

Authors:  Kelly Huang; Len Incognito; Xing Cheng; Nancy D Ulbrandt; Herren Wu
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

6.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

7.  Host and Viral Factors in Respiratory Syncytial Virus Infection.

Authors:  Peter Mastrangelo; Richard G Hegele
Journal:  Curr Pediatr Rep       Date:  2013-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.